Twist Bioscience Named in Inc.’s First Annual Best-Led Companies List
November 02 2021 - 7:00AM
Business Wire
First-ever roundup of companies that
established management excellence across the middle market
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced that it has been
included in Inc.’s first annual Best-Led Companies list, an
exciting 12-point measure of management excellence across the
middle market — a select, data-driven list of the very strongest
U.S. firms with revenue of $50 million to $2 billion.
“I am thrilled that Twist has been included in Inc.’s inaugural
best-led companies list. Although this list honors leadership, our
success to date is due to the entire team at Twist, whose
commitment, hard work and innovation have made our company what it
is today,” said Emily M. Leproust, Ph.D., CEO and co-founder of
Twist Bioscience.
The final list recognizes 250 companies that are agile enough to
maneuver but also big enough to have a broad impact. These
companies employ 35 million people, about one in four U.S. workers.
All 250 have a successful track record with leadership teams that
spur solid performance, create value, penetrate markets, engage
with customers, and more. To be considered for the list, each
company had to fill out an application answering questions about
its performance, executive team, and leadership. Applicants were
then analyzed via an algorithm that identified the very best
companies according to their leadership teams’ superlative
accomplishments in four key areas: performance and value creation;
market penetration and customer engagement; talent; and leadership
team.
“This inaugural list of companies represents the remarkable
midsized companies, both public and private, often founder led,
that are at the vanguard of reinventing American business,” said
Scott Omelianuk, editor-in-chief of Inc. magazine. “With their
leadership, all business will benefit from an exciting, competitive
future full of possibilities.”
To compile the list, Inc. evaluated private and public
U.S.-based companies with a 2020 revenue of $50 million to $2
billion or a valuation of $50 million to $10 billion using a
proprietary 12-point measure of management excellence, generated
with input from partners at Pitchbook and Shango Labs.
The November issue of Inc. magazine is available online now at
https://www.inc.com/magazine and will be on newsstands beginning
November 9, 2021.
About Inc.
The world’s most trusted business-media brand, Inc., offers
entrepreneurs the knowledge, tools, connections, and community they
need to build great companies. Its award-winning multiplatform
content reaches more than 50 million people each month across
various channels, including websites, newsletters, social media,
podcasts, and print. Its prestigious Inc. 5000 list, produced every
year since 1982, analyzes company data to recognize the
fastest-growing privately held businesses in the United States. The
global recognition that comes with inclusion in the 5000 allows the
founders of the best businesses to engage with an exclusive
community of their peers and the credibility that helps them drive
sales and recruit talent. The associated Inc. 5000 Conference is
part of a highly acclaimed portfolio of bespoke events produced by
Inc. For more information, visit www.inc.com.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements involve known and unknown
risks, uncertainties, and other important factors that may cause
Twist Bioscience’s actual results, performance, or achievements to
be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
risks and uncertainties of the ability to attract new customers and
retain and grow sales from existing customers; risks and
uncertainties of rapidly changing technologies and extensive
competition in synthetic biology could make the products Twist
Bioscience is developing obsolete or non-competitive; the retention
of employees of acquired companies and the ability of Twist
Bioscience to successfully integrate acquired companies and to
achieve expected benefits, risks of third party claims alleging
infringement of patents and proprietary rights or seeking to
invalidate Twist Bioscience’s patents or proprietary rights; and
the risk that Twist Bioscience’s proprietary rights may be
insufficient to protect its technologies. For a further description
of the risks and uncertainties that could cause actual results to
differ from those expressed in these forward-looking statements, as
well as risks relating to Twist Bioscience’s business in general,
see Twist Bioscience’s risk factors set forth in Twist Bioscience’s
Quarterly Report Form 10-Q filed with the Securities and Exchange
Commission on August 9, 2021, and subsequent filings with the SEC.
Any forward-looking statements contained in this press release
speak only as of the date hereof, and Twist Bioscience specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211102005531/en/
Twist Bioscience Angela Bitting SVP, Corporate Affairs
925-202-6211 media@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024